Otsuka, Shape Ink Potential $1.5B Deal to Develop Eye AAV Gene Therapies

To build its ophthalmology portfolio, Japan’s Otsuka Pharmaceuticals has teamed with RNA editing biotech Shape Therapeutics to develop adeno-associated virus gene therapies for ocular diseases.

Related Keywords

Osaka ,Japan ,Japanese ,Francois Vigneault ,Toshiki Sudo ,Sumitomo Pharma ,Japan Otsuka Pharmaceuticals On ,Osaka Research Center ,Otsuka Pharmaceuticals ,Shape Therapeutics ,Drug Discovery ,Resume ,Careers ,Tsuka ,Hape Ink Potential 1 5b Deal To Develop Eye Aav Gene Therapies ,Iospace ,Advice ,